American Journal of Tropical Medicine and Hygiene
June 2016; 94 (6)
http://www.ajtmh.org/content/current

.
Editorial
The Development of Small Animal Models for Zika Virus Vaccine Efficacy Testing and Pathological Assessment
Am J Trop Med Hyg 2016 94:1187-1188; Published online May 2, 2016, doi:10.4269/ajtmh.16-0277
Aaron C. Brault and Richard A. Bowen

.

Long-Term Safety and Immunogenicity of a Tetravalent Live-Attenuated Dengue Vaccine and Evaluation of a Booster Dose Administered to Healthy Thai Children
Am J Trop Med Hyg 2016 94:1348-1358; Published online March 28, 2016, doi:10.4269/ajtmh.15-0659
Veerachai Watanaveeradej, Sriluck Simasathien, Mammen P. Mammen, Jr., Ananda Nisalak, Elodie Tournay, Phirangkul Kerdpanich, Rudiwilai Samakoses, Robert J. Putnak, Robert V. Gibbons, In-Kyu Yoon, Richard G. Jarman, Rafael De La Barrera, Philippe Moris, Kenneth H. Eckels, Stephen J. Thomas, and Bruce L. Innis
Abstract
We evaluated the safety and immunogenicity of two doses of a live-attenuated, tetravalent dengue virus vaccine (F17/Pre formulation) and a booster dose in a dengue endemic setting in two studies. Seven children (7- to 8-year-olds) were followed for 1 year after dose 2 and then given a booster dose (F17/Pre formulation), and followed for four more years (Child study). In the Infant study, 49 2-year-olds, vaccinated as infants, were followed for approximately 3.5 years after dose 2 and then given a booster dose (F17) and followed for one additional year. Two clinically notable events were observed, both in dengue vaccine recipients in the Infant study: 1 case of dengue approximately 2.7 years after dose 2 and 1 case of suspected dengue after booster vaccinations. The booster vaccinations had a favorable safety profile in terms of reactogenicity and adverse events reported during the 1-month follow-up periods. No vaccine-related serious adverse events were reported during the studies. Neutralizing antibodies against dengue viruses 1–4 waned during the 1–3 years before boosting, which elicited a short-lived booster response but did not provide a long-lived, multivalent antibody response in most subjects. Overall, this candidate vaccine did not elicit a durable humoral immune response

.

Improving Capture of Vaccine History: Case Study from an Evaluation of 10-Valent Pneumococcal Conjugate Vaccine Introduction in Kenya
Am J Trop Med Hyg 2016 94:1400-1402; Published online May 2, 2016, doi:10.4269/ajtmh.15-0783
Aaron M. Harris, George Aol, Dominic Ouma, Godfrey Bigogo, Joel M. Montgomery, Cynthia G. Whitney, Robert F. Breiman, and Lindsay Kim
Abstract
With the accelerated introduction of new vaccines in low-income settings, understanding immunization program performance is critical. We sought to improve immunization history acquisition from Ministry of Health vaccination cards during a vaccine impact study of 10-valent pneumococcal conjugate vaccine on pneumococcal carriage among young children in Kenya in 2012 and 2013. We captured immunization history in a low proportion of study participants in 2012 using vaccination cards. To overcome this challenge, we implemented a household-based reminder system in 2013 using community health workers (CHWs), and increased the retrieval of vaccine cards from 62% in 2012 to 89% in 2013 (P < 0.001). The home-based reminder system using CHWs is an example of an approach that improved immunization history data quality in a resource-poor setting.